Affiliation:
1. Veneto Institute of Oncology IOV – IRCCS
2. Veneto Institute of Oncology IOV - IRCCS
Abstract
Abstract
Background: Immune checkpoint inhibitors (ICIs) are widely used in non-oncogene addicted Non-small cell lung cancer and characterized by high heterogeneity in clinical benefit. Different combination strategies are available in first-line setting and PD-L1 is the only predictive marker used in clinical practice.
Methods: Patients with NSCLC treated with ICI single-agent according to clinical practice were prospectively enrolled. Liquid biopsy was performed at the time of first dose administration (T1), after 3 weeks (T2) and at the time of radiological evaluation (T3). Cell free DNA (cfDNA) was quantified (ng/ml) by qPCR and analysed by NGS targeted panel.
Molecular variables used for association with outcome endpoints were: cfDNA quantification as static parameter, dynamic cfDNA change (DT2-T1), variant allele frequency of the gene with the highest frequency at base line (MaxVAF) and dynamic maxVAF change (DT2-T1). Cox regression analysis was used to build integrated predictive models.
Results: 113 patients were included. At multivariate analysis, PD-L1 negativity, T1 cfDNA, cfDNA increase (DT2-T1), and maxVAF at T2 were significantly associated with shorter PFS; PD-L1 negativity, squamous histology, T1 cfDNA, increase of cfDNA (DT2-T1), and maxVAF at T2 were significantly associated with worse OS. Integrated model permitted to build a nomogram and establish three groups of patients deriving different clinical benefit from ICI. The model was tested in patients expressing PD-L1 ³50% and treated with first-line pembrolizumab (n=57) and was able to identify elevated maxVAF at T2 and increase (DT2-T1) of cfDNA as independently associated with worse PFS; higher levels of maxVAF at T2 and increase (DT2-T1) of cfDNA with worse OS. Derived integrated model was able to identify patients with different clinical benefit (high, intermediate, low risk).
Conclusions: We developed an integrated nomogram to stratify NSCLC patients deriving different clinical benefit from ICIs which outperforms individual predictive markers.
Publisher
Research Square Platform LLC
Reference32 articles.
1. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Hendriks LE;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2023
2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma;Govindan R;J. Immunother. Cancer,2022
3. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50;Reck M;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2021
4. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer;Gandhi L;N. Engl. J. Med.,2018
5. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok TSK;Lancet Lond. Engl.,2019